Alluvi, formerly BI 4744, represents a significant development in obesity care. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide targets demonstrates compelling effectiveness in https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/